3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
8
Polycystic Ovary Syndrome
3
Peripheral Nervous System Diseases
2
Obesity
2
Neoplasms
2
Head and Neck Neoplasms
2
Triple Negative Breast Neoplasms
1
Tracheal Diseases
1
TP53 Y220C Mutation
1
Squamous Cell Carcinoma of Head and Neck
1
Smoking
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Pulmonary Disease, Chronic Obstructive
1
Pancreatic Neoplasms
1
Overweight
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Multiple Myeloma
1
Mesothelioma
1
Meningioma
1
Medulloblastoma
1
Lymphoma, Mantle-Cell
1
Lung Neoplasms
1
Interventions
Doxorubicin
27
pembrolizumab
24
Radiotherapy
20
Cyclophosphamide
18
Magnetic Resonance Spectroscopy
17
Specimen Handling
14
Nivolumab
14
Ifosfamide
13
Gemcitabine
13
Biopsy
11
Surgical Procedures, Operative
10
Radiation
10
Temozolomide
9
X-Rays
8
Ipilimumab
8
pazopanib
7
fludarabine
7
cabozantinib
7
Irinotecan
7
Blood Specimen Collection
7
tazemetostat
6
liposomal doxorubicin
6
Trabectedin
6
Surveys and Questionnaires
6
Phantoms, Imaging
6
olaparib
5
eribulin
5
atezolizumab
5
Vincristine
5
Standard of Care
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
Tablets
×
1 year
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled